Cambrex (NYSE:CBM) was downgraded by equities researchers at Longbow Research from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports.
Several other research firms have also recently commented on CBM. William Blair began coverage on Cambrex in a research note on Tuesday, January 16th. They set an “outperform” rating for the company. Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday, January 15th. Finally, Craig Hallum restated a “buy” rating and set a $60.00 price target (down previously from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. Cambrex has an average rating of “Hold” and an average target price of $60.00.
Cambrex (NYSE:CBM) traded down $1.45 during mid-day trading on Wednesday, hitting $53.50. The stock had a trading volume of 522,544 shares, compared to its average volume of 393,495. The firm has a market capitalization of $1,747.45, a P/E ratio of 17.43, a P/E/G ratio of 1.24 and a beta of 2.38. Cambrex has a 1-year low of $42.55 and a 1-year high of $62.95.
Institutional investors have recently added to or reduced their stakes in the company. Advisor Group Inc. raised its stake in shares of Cambrex by 29.8% during the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 615 shares during the last quarter. Financial Gravity Companies Inc. purchased a new stake in shares of Cambrex during the fourth quarter worth approximately $166,000. Visionary Asset Management Inc. purchased a new stake in shares of Cambrex during the third quarter worth approximately $201,000. MML Investors Services LLC purchased a new stake in shares of Cambrex during the fourth quarter worth approximately $204,000. Finally, Two Sigma Securities LLC purchased a new stake in shares of Cambrex during the fourth quarter worth approximately $207,000.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.